Health Blueprint

Back to Longevity News

News summary

Kesmalea Therapeutics Announces $60 Million Series A Financing to Advance Next-Generation Targeted Protein Degraders for Alzheimer’s and Other Neurodegenerative Diseases and Rebrands as Oyster Therapeutics

Source: BioSpace - Funding • Published: 10 Nov 2026, 11:54

Summarized by Masters of Longevity from BioSpace - Funding.

Company closed a $60 million financing and rebranded to Oyster Therapeutics.

Kesmalea Therapeutics Announces $60 Million Series A Financing to Advance Next-Generation Targeted Protein Degraders for Alzheimer’s and Other Neurodegenerative Diseases and Rebrands as Oyster Therapeutics
Key Takeaways
  • The $60 million Series A-2 financing was led by 4BIO Capital.
  • Proceeds will advance an oral, brain‑penetrant tau degrader to clinic.
  • A sponsored research agreement with MGH was established for tau.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.